Ucb Inc
9 products tracked · names used in filings: Ucb Inc, UCB Pharma, UCB Pharma SA, UCB Pharma Ltd
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Thu 26 Mar 2026🇪🇺 EU approval (EC decision)
Kygevvi (doxecitine;doxribtimine) approved in the EU
Marketing authorisation to UCB Pharma; Orphan, PRIME, Exceptional circumstances · source
Thu 29 Jan 2026🇪🇺 CHMP positive opinion
Kygevvi (doxecitine;doxribtimine): CHMP positive opinion
UCB Pharma; Orphan, PRIME, Exceptional circumstances · source
Mon 03 Nov 2025🇺🇸 FDA approval
FDA approves Kygevvi (doxecitine, doxribtimine), a new medicine
Ucb Inc; NDA219792; New molecular entity, Priority review; for solution · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Cimzia certolizumab pegol | Refused | |
| 🇪🇺 | Kygevvi doxecitine;doxribtimine | Authorised | 2026-03-26 |
| 🇺🇸 | Kygevvi doxecitine, doxribtimine | Approved | 2025-11-03 |
| 🇪🇺 | Rystiggo rozanolixizumab | Authorised | 2024-01-05 |
| 🇪🇺 | Briviact (in Italy: Nubriveo) brivaracetam | Authorised | 2016-01-13 |
| 🇪🇺 | Cimzia certolizumab pegol | Authorised | 2009-10-01 |
| 🇪🇺 | Vimpat lacosamide | Authorised | 2008-08-29 |
| 🇪🇺 | Xyrem sodium oxybate | Authorised | 2005-10-13 |
| 🇪🇺 | Keppra levetiracetam | Authorised | 2000-09-29 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.